Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin
Urine cancer DNA testing detects bladder cancer recurrence months earlier than standard surveillance, giving doctors a significant head start to intervene before tumors progress.
In this multicenter validation study, urine tumor DNA (utDNA) analysis reliably stratified recurrence risk after BCG treatment for high-risk NMIBC, providing a 4.1-month lead time over standard cystoscopy/cytology surveillance. Post-BCG utDNA positivity carries a 10-fold higher HR for recurrence, enabling earlier personalized treatment intensification decisions in a cancer type affecting ~200,000 new patients annually in the US.
What the study was
- Study design
- Multicenter retrospective validation cohort study
- Population
- Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) receiving intravesical BCG
- Sample size
- 57
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Journal of Urology
Why it surfaced
Multicenter validation of urinary ctDNA for NMIBC monitoring post-BCG with strong HR (10.0); 4.1-month lead time over SOC enables earlier intervention; J Urol publication (high-impact urology journal); directly actionable in clinical surveillance protocols.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.